Press Releases and Ad-hoc Announcements

28 October 2021	PR: Heidelberg Pharma Participates at Various Conferences	PDF	Read More
07 October 2021	PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021	PDF	Read More
01 October 2021	PR: Heidelberg Pharma AG Announces Adjustment of Guidance	PDF	Read More
09 September 2021	PR: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences	PDF	Read More
07 September 2021	PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US	PDF	Read More
19 July 2021	PR: Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101	PDF	Read More
08 July 2021	PR: Heidelberg Pharma Reports on First Half-Year 2021	PDF	Read More
17 June 2021	PR: Heidelberg Pharma Announces Participation at Various Conferences	PDF	Read More
15 June 2021	Heidelberg Pharma AG Raises EUR 20 Million From Private Placement	PDF	Read More
15 June 2021	AH: Heidelberg Pharma AG to Raise Capital in a Private Placement	PDF	Read More
18 May 2021	PM: Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions	PDF	Read More
29 April 2021	PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021	PDF	Read More
31 March 2021	PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021	PDF	Read More
25 March 2021	PR: Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update	PDF	Read More
19 March 2021	AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini	PDF	Read More
01 March 2021	PR: Heidelberg Pharma Expands Management Team	PDF	Read More
11 February 2021	PR: Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine	PDF	Read More
04 February 2021	AH: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101	PDF	Read More

© Heidelberg Pharma AG. All rights reserved.